Loading...
Market
How many countries will approve Ozempic for Alzheimer's prevention by end of 2025?
2
Resolution / Starting Odds
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
Official health department announcements from various countries
Story
Novo Nordisk's Ozempic Linked to Significantly Reduced Alzheimer's Risk in Type 2 Diabetes Patients
Oct 24, 2024, 11:08 AM
Novo Nordisk's diabetes medication, Ozempic, has been linked to a significantly reduced risk of Alzheimer's disease, according to a new observational study. The research highlights the drug's potential effects beyond its primary uses for type 2 diabetes and obesity. This finding adds to the growing body of evidence surrounding Ozempic, which is already popular for its benefits in managing diabetes and assisting with weight loss. The study's results are particularly relevant for patients with type 2 diabetes, who may face an increased risk of developing Alzheimer's disease.
View original story
Similar markets
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
Yes • 50%
No • 50%
Adopted in US and EU • 25%
Adopted in US only • 25%
Adopted in EU only • 25%
Not adopted • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
More than 5 trials • 25%
3 to 5 trials • 25%
1 to 2 trials • 25%
No new trials • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%